Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$18.1MCash on Hand
10.8mo Cash Runway
Follow LGVN by emailGet an email when LGVN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LGVN, unsubscribe in one click. Privacy
📣 What LGVN Says Is Next
in 2027 · “The Company currently anticipates initiation of the Phase 2 clinical trial in 2027, with planning and preparation beginning in 2026.”
Company press release, Aug 12, 2026 · SEC filing
fourth quarter of 2026 · “The net proceeds from the initial tranche of the financing are expected to fund the Company’s current operating plans into the fourth quarter of 2026, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout.”
Company press release, Mar 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 12, 2026 ·
Earnings Longeveron reported Q3 2026 revenue of $0.1 million, down 16% as contract manufacturing revenue disappeared, and G&A of $3.3 million. It said the FDA will be asked to review ELPIS II results for HLHS and that a strategic review with Lucid Capital Markets as financial advisor is underway. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Leadership Director Ursula Ungaro resigned immediately on November 1, 2026, from the board and its Audit, Compensation, Nominating and Corporate Governance, and Special committees, citing personal health issues and no disagreement with the company. Form 8-K · SEC filing
Oct 26, 2026 ·
Clinical trial Longeveron said ELPIS II missed its primary RVEF endpoint at 12 months, but a pre-specified secondary endpoint, MACE, reached significance with 8 events in the standard of care arm versus 1 with laromestrocel (P=0.043). The company plans to request an FDA meeting on next steps. Form 8-K · SEC filing · Press release
Oct 14, 2026 ·
Leadership Dr. Nataliya Agafonova informed management on October 7, 2026 of her decision to step down as Chief Medical Officer, effective October 14, 2026. Form 8-K · SEC filing
Sep 23, 2026 ·
Clinical trial ELPIS II Phase 2b trial of laromestrocel in infants with HLHS missed its primary endpoint, with RVEF change at Month 12 showing a -0.7 percentage point difference (95% CI: -7.3 to 5.9; p=0.8336). The company will discuss next steps with the FDA and is initiating a review of all options to maximize shareholder value. Form 8-K · SEC filing · Press release
Sep 14, 2026 ·
Listing Longeveron regained compliance with Nasdaq's $1.00 minimum bid price requirement. Nasdaq confirmed a closing price of $1.00 or greater for 10 consecutive business days, from August 27, 2026 through September 10, 2026, and closed the matter. Form 8-K · SEC filing
Aug 24, 2026 ·
Listing Longeveron approved a 1-for-10 reverse stock split effective 11:59 p.m. ET on August 26, 2026, with Class A stock trading under new CUSIP 54303L 302 on Nasdaq from August 27. The split aims to regain compliance with the $1.00 minimum bid price. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2026 · Phase 2 · Active Trial · Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial. Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
LGVN holds $18.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $5M/quarter from operations,
an estimated runway of 10.8 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 11 months +30
ATM program on file since Sep 2025 +15
Shelf registration (S-3, Mar 2025) +10
Going-concern doubt in the latest 10-Q +15As a result, there is substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LGVN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.